Design of putative T-cell epitope-based vaccine against SARS-CoV-2 : reverse vaccinology approach

Khaerunissa Anbar Istiadi1, Fadilah Fadilah1,2, Rafika Indah Paramita1,2, Linda Erlina1,2, Budi Wiweko3

1Bioinformatics Core Facilities – IMERI, Faculty of Medicine, Universitas Indonesia. Jalan Salemba Raya number 6, Jakarta, Indonesia

2Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia. Jalan Salemba Raya number 4, Jakarta, Indonesia

3Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia


Late 2019, severe pneumonia cases were found in Wuhan, China. The cases then identified as COVID-19, caused by a novel Coronavirus, SARS-CoV-2. Until now, there has been no efficacious and approved therapy to control SARS-CoV-2 spread. The rapid global spread and vulnerability of infection made an urgency to produce drugs or vaccine, enhancing global immune system. Currently researchers and companies are working to develop a vaccine for SARS-CoV-2. Most of this vaccine target the Spike protein aim to elicit protective antibodies. S protein (S) might be used as target for vaccine development since it is the outer surface protein of SARS-CoV-2 which can be directly recognized by the immune system. Here an attempt has been made to design putative epitope-based vaccine for SARS-CoV-2, analyzing virus genome using reverse vaccinology approach based on SARS-CoV-2 virus spike protein sequence data. About 6000 sequences were downloaded from ViPR database and processed by AVANA to find conserved region. Based on predictions through the reverse vaccinology approach and molecular docking, HLA Class I putative epitope YQPYRVVVL which overlap with HLA Class II putative epitope NGVGYQPYRVVVLSF sequence was selected as potential peptide-vaccine candidates.

Keywords: HLA, Reverse vaccinology, SARS-CoV-2, Spike protein, T-cell epitope-based vaccine

Recent Comments